Atypical antipsychotic – dopamine partial agonist
ATC code: N05AX12 (Aripiprazole)
A partial agonist at dopamine D2 and serotonin 5-HT1A receptors and 5-HT2A antagonist. Unlike classical D2 antagonists (haloperidol, risperidone), it acts as a dopamine stabilizer: reducing transmission with hyperactivity (psychosis) and increasing it with hypoactivity (motivational deficit). Compared with other atypical antipsychotics, less weight gain, metabolic disturbance, and prolactinemia. CYP3A4- and CYP2D6-metabolized, half-life 75 hours.
First line
First-line for acute mania and maintenance therapy of bipolar I disorder per CANMAT 2018. Dose 15–30 mg once daily. Effective in preventing manic episodes; inferior to lamotrigine for preventing depressive episodes.
Second line
Used as antidepressant augmentation in inadequate response to SSRIs or SNRIs (treatment-resistant depression). Dose 2–5 mg daily. Efficacy shown in several RCTs (CN138-139, CN138-141). Not used as monotherapy for major depressive disorder.
First line
First-line for schizophrenia and schizoaffective disorder per 2020 and NG178 (2020). Starting dose 10–15 mg once daily, titrated to 15–30 mg. Long-acting injectable (Abilify Maintena 400 mg every 4 weeks) for patients with adherence issues. The Huhn 2019 network meta-analysis showed efficacy comparable to other atypical antipsychotics with better metabolic profile.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Aripiprazole is an antipsychotic. It is prescribed for schizophrenia, bipolar disorder, as an add-on to antidepressants for treatment-resistant depression, and for autism spectrum disorder in children ( 2020 and NG178 guidelines). For acute stress or anxiety, aripiprazole has no proven efficacy: no clinical studies of such use exist. The drug has serious side effects: akathisia (a distressing sensation of inner restlessness), metabolic syndrome, pathological gambling and other compulsive behaviors ( warning, 2016). If aripiprazole was prescribed for these indications, consider seeking a second opinion.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
Boxed warning
FDA boxed warning: increased mortality in elderly patients with dementia treated with atypical antipsychotics. Aripiprazole is not approved for dementia-related psychosis.
Limited pregnancy data. T3 use carries neonatal extrapyramidal and withdrawal risk. In pregnant psychotic patients, decisions are made with the psychiatrist.
Milk concentrations are low. Use during lactation is possible when needed, with monitoring of infant sedation and weight gain.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Aripiprazole is evaluated for the following indications with varying evidence strength: Bipolar disorder maintenance (evidence tier A), Major depressive disorder (evidence tier A), Schizophrenia (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Aripiprazole (≥ 1 in 100): Insomnia, Anxiety and akathisia, Headache, Nausea, Constipation, Drowsiness. See the Safety section for uncommon and serious reactions.
FDA category C. Limited pregnancy data. T3 use carries neonatal extrapyramidal and withdrawal risk. In pregnant psychotic patients, decisions are made with the psychiatrist.
Milk concentrations are low. Use during lactation is possible when needed, with monitoring of infant sedation and weight gain.
Aripiprazole is contraindicated in: Aripiprazole hypersensitivity; Pregnancy (except life-saving indications); Lactation; Age under 13 (schizophrenia), under 10 (bipolar) – per EMA. Full list in the Safety section.
FDA boxed warning: increased mortality in elderly patients with dementia treated with atypical antipsychotics. Aripiprazole is not approved for dementia-related psychosis.